Key result
Low FDG uptake on positron emission tomography was helpful to differentiate giant hepatic cavernous hemangioma from malignant hepatic tumors in two cases.
Why the study?
Does FDG PET help differentiate giant hepatic cavernous hemangioma from malignant hepatic tumors?
Case Report (n=2)
Does FDG PET help differentiate giant hepatic cavernous hemangioma from malignant hepatic tumors?
Low FDG uptake on PET imaging may help differentiate giant hepatic cavernous hemangiomas from malignant liver tumors like angiosarcoma.
May support FDG PET differentiation of giant hepatic cavernous hemangioma; hypothesis-generating case report requiring prospective validation.
Giant cavernous hemangioma of the liver sometimes has a very inhomogeneous appearance with intratumoral degeneration on computed tomography or magnetic resonance imaging, and may mimic a malignant hepatic tumor, including angiosarcoma. There are many reports about F-18 fluorodeoxyglucose (FDG) uptake of angiosarcoma; however, knowledge regarding positron emission tomography findings with FDG for giant hepatic cavernous hemangioma is still limited. We herein present 2 cases of giant hepatic cavernous hemangioma in which low FDG uptake was considered helpful to differentiate from malignant hepatic tumor.
No takes yet. Share an insight, caveat, or question.
Shimada et al. (2010) conducted a case report in Giant hepatic cavernous hemangioma (n=2). F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) was evaluated on FDG uptake. Low FDG uptake on positron emission tomography was helpful to differentiate giant hepatic cavernous hemangioma from malignant hepatic tumors in two cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: